Company intelligence / Profile preview

Atlanta Catheter Therapies

Chattanooga, Tennessee, United States

Ownership: Private
Development stage: Other

Overview

The Pressana Occlusion Perfusion Catheter (OPC) has three FDA 510(k) clearances, demonstrated safety and efficacy in studies like COPPER-A for below-the-knee PAD treatment, and is actively marketed for delivering liquid therapeutic agents such as paclitaxel and sirolimus to prevent restenosis.[1][3]

Therapeutic areas: Cardiovascular
Industry: Therapeutic Medical Devices

Partnerships

Cardiovascular Institute of the South (KOL)

Beyond the preview

Go deeper on Atlanta Catheter Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atlanta Catheter Therapies.

Explore the full profile